Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2022
ICER publishes evidence report on treatments for obesity management
31 August 2022 - Greater weight loss was seen with semaglutide and with phentermine/topiramate; less weight loss was seen with liraglutide ...
Posted by Michael Wonder on 26 Aug 2022
PBAC Public Summary Documents – May 2022 meeting
26 August 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the May 2022 PBAC ...
Posted by Michael Wonder on 12 Aug 2022
2022-2023 cost recovery implementation statement
12 August 2022 - The 2022-23 PBS and NIP cost recovery implementation statement is now available. ...
Posted by Michael Wonder on 19 Jul 2022
ICER publishes final evidence report and policy recommendations on beti-cel gene therapy for beta thalassaemia
19 July 2022 - Independent appraisal committee unanimously determined that evidence is adequate to demonstrate that beti-cel provides a net ...
Posted by Michael Wonder on 15 Jul 2022
PBAC Public Summary Documents (first time rejections and deferrals) – March 2022 meeting
15 July 2022 - The Public Summary Documents (first time rejections and deferrals) from the March 2022 PBAC meeting are now ...
Posted by Michael Wonder on 13 Jul 2022
ICER releases draft evidence report on treatments for obesity management
13 July 2022 - Registration now open for 26 July “Early Insights” webinar. ...
Posted by Michael Wonder on 11 Jul 2022
Drug Utilisation SubCommittee outcome statement
8 July 2022 - The outcome statement from the June 2022 DUSC meeting is now available. ...
Posted by Michael Wonder on 01 Jul 2022
Public Summary Documents – March 2022 PBAC meeting
1 July 2022 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the March 2022 PBAC ...
Posted by Michael Wonder on 14 Jun 2022
ICER releases draft evidence report on treatments for amyotrophic lateral sclerosis
14 June 2022 - Public comment period now open until 13 July 2022; requests to make oral comment during public ...
Posted by Michael Wonder on 02 Jun 2022
ICER publishes evidence report on gene therapy for beta thalassaemia
2 June 2022 - Evidence judged to demonstrate that beti-cel provides net health benefit to patients with transfusion-dependent thalassaemia. ...
Posted by Michael Wonder on 28 May 2022
Where is the PHARMAC review?
28 May 2022 - “It has been three months to the day since the Minister received the PHARMAC review, why ...
Posted by Michael Wonder on 10 May 2022
Calls for Health Minister to release final report from PHARMAC review
11 May 2022 - Health Minister Andrew Little is facing calls to release the final report from a review of ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Abecma in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for Abecma (idecabtagene vicleucel). ...
Posted by Michael Wonder on 09 May 2022
Health economic assessment of Blenrep in the treatment of multiple myeloma
6 May 2022 - TLV has produced a health economic assessment for the regions for the drug Blenrep (belantamab mafodotin). ...
Posted by Michael Wonder on 14 Apr 2022
Public summary documents – December 2021 PBAC meeting (first time decisions not to recommend, deferrals and other matters)
14 April 2022 - The Public Summary Documents (first time decisions not to recommend, deferrals and other matters) from the December ...